top of page
ATI-1801
ATI-1801
PIPELINE
ATI-1501
ATI-1701
ATI-1801
STRATEGY
Diverse Pipeline
Business Environment
ABOUT US
Leadership
Board of Directors
COLLABORATORS
INVESTORS
Financial Reports
Proxy Information
Corporate Governance
Legal Counsel & Auditors
Analyst Coverage
SEDAR Filings
Contact IR
NEWS
News 2023
Archives 2022
Archives 2021
Archives 2020
Archives 2019
Archives 2018
Archives 2017
Archives 2016
Media Contact
CONTACT
CAREERS
Career Opportunities
More
Use tab to navigate through the menu items.
News Highlights
News 2021
Archives 2020
Archives 2019
Archives 2016-2018
Media Contact
Media Download Center
News Highlights
News 2022
Archives 2021
Archives 2020
Archives 2019
Archives 2016-2018
Media Contact
Media Download Center
Archives 2019
Archives 2018
Archives 2017
Archives 2016
October 9, 2018
Appili Therapeutics Appoints Seasoned Infectious Disease Global Drug Development Executive Dr. Theresa Matkovits to Its Board of Directors
Read More
October 1, 2018
Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer
Read More
August 16, 2018
Appili Therapeutics Announces Results of 2018 Annual and Special Meeting
Read More
July 30, 2018
Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension
Read More
June 21, 2018
Appili Therapeutics to Present at 2018 Atlantic Venture Forum Technology Showcase
Read More
April 18, 2018
Appili Therapeutics to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference
Read More
February 7, 2018
Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline
Read More
January 26, 2018
Appili Recognized as ‘New Business of the Year’ by the Halifax Chamber of Commerce
Read More
January 9, 2018
Appili Therapeutics Licenses BioTerrorism Vaccine Rights
Read More
bottom of page